Picture Berlin Partner HealthCapital Voices from Berlin-Brandenburg 650x80px
Document › Details

Fluidigm Corporation. (12/14/18). "Press Release: Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares". South San Francisco, CA.

Organisations Organisation Fluidigm Corporation (Nasdaq: FLDM)
  Group Fluidigm (Group)
  Organisation 2 Piper Jaffray & Co. (NYSE: PJC)
Products Product mass cytometry
  Product 2 investment banking
Index term Index term Fluidigm–SEVERAL: investment, 201812 public offering $63.3m net $59.1m with 8.15m+1.225m shares common stock at $6.75/share
Person Person Lee, Agnes (Fluidigm 201806 VP Investor Relations)

Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock. The stock was sold at a price to the public of $6.75 per share, for aggregate gross proceeds of approximately $63.3 million, from the company’s existing shelf registration statement. The shares include 1,222,500 shares of common stock sold pursuant to an over-allotment option granted by Fluidigm to the underwriters, which option was exercised in full. Net proceeds from the offering were approximately $59.1 million after deducting underwriting discounts and commissions and the estimated expenses of the offering. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies, and to fund possible investments in or acquisitions of complementary businesses, products, or technologies.

Piper Jaffray and UBS Investment Bank acted as joint book-running managers for the offering. BTIG and Janney Montgomery Scott acted as co-managers.

A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on March 8, 2017, amended on April 28, 2017 and declared effective by the SEC on May 2, 2017. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at Copies of the final prospectus supplement and accompanying prospectus may also be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by phone at 1-800-747-3924, or by email at, and from UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, 25th floor, New York, NY 10019, or by phone at 888-827-7275 or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


Agnes Lee
Vice President, Investor Relations
Phone: 650-416-7423

Record changed: 2019-01-29


Picture [iito] Made Without Love 650x100px

More documents for Fluidigm (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BioTech Showcase 2022 For Innovators 650x300

» top